Who is sponsoring Isradipine?

Isradipine is sponsored by Massachusetts General Hospital.

What condition does Isradipine study?

Isradipine studies Bipolar Disorder.

What drugs are being tested in Isradipine?

Interventions: Isradipine, Placebo.

What is the status of Isradipine?

Isradipine is currently TERMINATED.

Last reviewed 2017-04-18 · How we verify

Adjunctive Isradipine for the Treatment of Bipolar Depression

NCT01784666 Phase 2 TERMINATED Results posted

This study investigates the medication isradipine, which is currently approved by the FDA to treat high blood pressure, in the treatment of depression in bipolar disorder. Isradipine or placebo (contains no active medication) will be used as an "add-on" to lithium, valproate, and/or atypical antipsychotics for individuals currently experiencing a major depressive episode. Our hypothesis is that isradipine will be superior to placebo in improving depressive symptoms.

Details

Lead sponsor	Massachusetts General Hospital
Phase	Phase 2
Status	TERMINATED
Enrolment	2
Start date	2013-02
Completion	2014-04

Conditions

Bipolar Disorder

Interventions

Isradipine
Placebo

Primary outcomes

Change in MADRS (4 Weeks) — Baseline vs week 4 (and, for placebo nonresponders in 1st 4 weeks, week 8 vs week 4)
Change in Montgomery-Asberg Depression Rating Scale (MADRS) in isradipine-treated epochs versus placebo-treated epochs. These scores represent total scores, and on the MADRS total scores range from 0-60. A higher score indicates increased depression severity.

Countries

United States